Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients

Mohammadinejad, Payam; Arya, Pantea; Esfandbod, Mohsen; Kaviani, Ahmad; Najafi, Masoome; Kashani, Ladan; Zeinoddini, Atefeh; Emami, Seyed Amirhossein; Akhondzadeh, Shahin

doi:10.1177/1060028015592215

Cited by 38 publications

(45 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Theoretically, higher doses of aspirin might inhibit COX‐2 and thereby increases leukocyte recruitment into the brain potentially causing tissue damage . The non‐aspirin NSAIDs may exert similar effects as these drugs are nonselective inhibitors of both COX‐1 and COX‐2 . Further, non‐aspirin NSAIDs are primarily used for moderate to severe pain, and, as noted, pain increases the risk of diverse mood and anxiety disorders …”

Section: Discussionmentioning

confidence: 99%

New drug candidates for bipolar disorder—A nation‐wide population‐based study

et al. 2019

View full text Add to dashboard Cite

Objective Drug repurposing is an increasingly promising idea in many fields of medicine. We systematically used Danish nation‐wide population‐based registers to investigate whether continued use of non‐aspirin non‐steroidal anti‐inflammatory drugs (NSAIDs), low‐dose aspirin, high‐dose aspirin, statins, allopurinol, and angiotensin agents decrease the rate of incident mania/bipolar disorder. Methods A nation‐wide population‐based longitudinal study using Poisson regression analyses including all persons in Denmark who purchased the exposure medication of interest and a random sample of 30% of the Danish population. The follow‐up period comprised a 10 years period from 2005 to 2015. Two different outcome measures were included, (1) a diagnosis of mania/bipolar disorder at a psychiatric hospital contact as inpatient or outpatient and (2) a combined measure of a diagnosis of mania/bipolar disorder or initiation of lithium use. Results A total of 1,605,365 subjects were exposed to one of the six drugs of interest during the exposure period from 2005 to 2015, median age 57 years [quartiles: 43;69], and female proportion of 53.1%. Continued use of low‐dose aspirin, statins, and angiotensin agents were associated with decreased rates of incident mania/bipolar disorder on both outcome measures. Continued uses of non‐aspirin NSAIDs as well as high‐dose aspirin were associated with an increased rate of incident bipolar disorder. There were no statistically significant associations for allopurinol. Conclusions The study supports the potential of agents acting on inflammation and the stress response system in bipolar disorder and illustrates that population‐based registers can be used to systematically identify drugs with repurposing potentials.

show abstract

Section: Discussionmentioning

confidence: 99%

New drug candidates for bipolar disorder—A nation‐wide population‐based study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The 4 studies showed a positive benefit for celecoxib at some point in the trial, although the one study conducted in Germany was plagued by a dropout rate of 50% in the celecoxib group and 60% in the placebo group (Muller et al, 2006), and of the remaining 3 studies, all of which were conducted in Iran, one showed no effect at 8 weeks (Hashemian et al, 2011); yet, for unclear reasons, in each meta-analysis, the more positive 4-week data from this study (that appear in the literature as an abstract) are included in the efficacy evaluation (Muller et al, 2006;Akhondzadeh et al, 2009;Hashemian et al, 2011;Abbasi et al, 2012). Of note, the Iranian group has also published positive data for celecoxib in OCD, acute bipolar mania, and depression in breast cancer, indicating an extraordinary efficacy that warrants further evaluation (Arabzadeh et al, 2015;Mohammadinejad et al, 2015;Shalbafan et al, 2015). Finally, there are some data to support that acetylsalicylic acid may augment the response to conventional antidepressant therapy, although this is a small literature that is in need of larger studies (Mendlewicz et al, 2006).…”

Section: Reviewmentioning

confidence: 99%

Therapeutic Implications of Brain–Immune Interactions: Treatment in Translation

Miller

Haroon

Felger

2016

Neuropsychopharmacol

118

124

View full text Add to dashboard Cite

A wealth of data has been amassed that details a complex, yet accessible, series of pathways by which the immune system, notably inflammation, can influence the brain and behavior. These data have opened the window to a diverse array of novel targets whose potential efficacy is tied to specific neurotransmitters and neurocircuits as well as specific behaviors. What is clear is that the impact of inflammation on the brain cuts across psychiatric disorders and engages dopaminergic and glutamatergic pathways that regulate motivation and motor activity as well as the sensitivity to threat. Given the ability to identify patient populations with increased inflammation, the precision of interventions can be further tuned, in conjunction with the ability to establish target engagement in the brain through the use of multiple neuroimaging strategies. After a brief overview of the mechanisms by which inflammation affects the brain and behavior, this review examines the extant literature on the efficacy of anti-inflammatory treatments, while forging guidelines for future intelligent clinical trial design. An examination of the most promising therapeutic strategies is also provided, along with some of the most exciting clinical trials that are currently being planned or underway.

show abstract

“…In addition, HDRS was administered at baseline and week 8 in order to assess changes in depressive symptoms. This clinician-rated scale contains 17 questions (measured either on 5-point or 3-point scales) that assess the severity of depression-related symptoms [24] and has been used in many trials in Iran [26][27][28][29][30][31]. Our primary outcome measure was the change in the PANSS negative subscale score from baseline to week 8 in the 2 groups.…”

Section: Discussionmentioning

confidence: 99%